vs

Side-by-side financial comparison of Dexcom (DXCM) and Teradyne (TER). Click either name above to swap in a different company.

Teradyne is the larger business by last-quarter revenue ($1.3B vs $1.3B, roughly 1.0× Dexcom). Teradyne runs the higher net margin — 31.1% vs 21.2%, a 9.9% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs 21.6%). Over the past eight quarters, Teradyne's revenue compounded faster (32.6% CAGR vs 12.0%).

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

DXCM vs TER — Head-to-Head

Bigger by revenue
TER
TER
1.0× larger
TER
$1.3B
$1.3B
DXCM
Growing faster (revenue YoY)
TER
TER
+65.5% gap
TER
87.0%
21.6%
DXCM
Higher net margin
TER
TER
9.9% more per $
TER
31.1%
21.2%
DXCM
Faster 2-yr revenue CAGR
TER
TER
Annualised
TER
32.6%
12.0%
DXCM

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
DXCM
DXCM
TER
TER
Revenue
$1.3B
$1.3B
Net Profit
$267.3M
$398.9M
Gross Margin
62.9%
60.9%
Operating Margin
25.6%
36.9%
Net Margin
21.2%
31.1%
Revenue YoY
21.6%
87.0%
Net Profit YoY
153.6%
EPS (diluted)
$0.67
$2.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DXCM
DXCM
TER
TER
Q1 26
$1.3B
$1.3B
Q4 25
$1.3B
$1.1B
Q3 25
$1.2B
$769.2M
Q2 25
$1.2B
$651.8M
Q1 25
$1.0B
$685.7M
Q4 24
$1.1B
$752.9M
Q3 24
$994.2M
$737.3M
Q2 24
$1.0B
$729.9M
Net Profit
DXCM
DXCM
TER
TER
Q1 26
$267.3M
$398.9M
Q4 25
$267.3M
$257.2M
Q3 25
$283.8M
$119.6M
Q2 25
$179.8M
$78.4M
Q1 25
$105.4M
$98.9M
Q4 24
$151.7M
$146.3M
Q3 24
$134.6M
$145.6M
Q2 24
$143.5M
$186.3M
Gross Margin
DXCM
DXCM
TER
TER
Q1 26
62.9%
60.9%
Q4 25
62.9%
57.2%
Q3 25
60.5%
58.4%
Q2 25
59.5%
57.2%
Q1 25
56.9%
60.6%
Q4 24
58.9%
59.4%
Q3 24
59.7%
59.2%
Q2 24
62.4%
58.3%
Operating Margin
DXCM
DXCM
TER
TER
Q1 26
25.6%
36.9%
Q4 25
25.6%
27.1%
Q3 25
20.1%
18.9%
Q2 25
18.4%
13.9%
Q1 25
12.9%
17.6%
Q4 24
17.0%
20.4%
Q3 24
15.3%
20.6%
Q2 24
15.7%
28.8%
Net Margin
DXCM
DXCM
TER
TER
Q1 26
21.2%
31.1%
Q4 25
21.2%
23.7%
Q3 25
23.5%
15.5%
Q2 25
15.5%
12.0%
Q1 25
10.2%
14.4%
Q4 24
13.6%
19.4%
Q3 24
13.5%
19.8%
Q2 24
14.3%
25.5%
EPS (diluted)
DXCM
DXCM
TER
TER
Q1 26
$0.67
$2.53
Q4 25
$0.67
$1.62
Q3 25
$0.70
$0.75
Q2 25
$0.45
$0.49
Q1 25
$0.27
$0.61
Q4 24
$0.37
$0.89
Q3 24
$0.34
$0.89
Q2 24
$0.35
$1.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DXCM
DXCM
TER
TER
Cash + ST InvestmentsLiquidity on hand
$917.7M
$241.9M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$2.7B
Total Assets
$6.3B
$4.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DXCM
DXCM
TER
TER
Q1 26
$917.7M
$241.9M
Q4 25
$917.7M
$293.8M
Q3 25
$1.8B
$272.7M
Q2 25
$1.2B
$339.3M
Q1 25
$904.9M
$475.6M
Q4 24
$606.1M
$553.4M
Q3 24
$621.2M
$510.0M
Q2 24
$939.2M
$421.9M
Total Debt
DXCM
DXCM
TER
TER
Q1 26
$0
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
DXCM
DXCM
TER
TER
Q1 26
$2.7B
Q4 25
$2.7B
$2.8B
Q3 25
$2.7B
$2.7B
Q2 25
$2.6B
$2.8B
Q1 25
$2.3B
$2.8B
Q4 24
$2.1B
$2.8B
Q3 24
$2.0B
$2.9B
Q2 24
$2.4B
$2.7B
Total Assets
DXCM
DXCM
TER
TER
Q1 26
$6.3B
$4.4B
Q4 25
$6.3B
$4.2B
Q3 25
$7.5B
$4.0B
Q2 25
$7.3B
$3.8B
Q1 25
$6.8B
$3.7B
Q4 24
$6.5B
$3.7B
Q3 24
$6.4B
$3.8B
Q2 24
$6.8B
$3.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DXCM
DXCM
TER
TER
Operating Cash FlowLast quarter
$265.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.66×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DXCM
DXCM
TER
TER
Q1 26
$265.1M
Q4 25
$294.0M
$281.6M
Q3 25
$659.9M
$49.0M
Q2 25
$303.0M
$182.1M
Q1 25
$183.8M
$161.6M
Q4 24
$301.4M
$282.6M
Q3 24
$199.5M
$166.3M
Q2 24
$279.4M
$216.1M
Free Cash Flow
DXCM
DXCM
TER
TER
Q1 26
Q4 25
$192.1M
$218.8M
Q3 25
$579.4M
$2.4M
Q2 25
$208.9M
$131.7M
Q1 25
$96.8M
$97.6M
Q4 24
$176.8M
$225.2M
Q3 24
$88.3M
$114.4M
Q2 24
$213.3M
$171.2M
FCF Margin
DXCM
DXCM
TER
TER
Q1 26
Q4 25
15.3%
20.2%
Q3 25
47.9%
0.3%
Q2 25
18.1%
20.2%
Q1 25
9.3%
14.2%
Q4 24
15.9%
29.9%
Q3 24
8.9%
15.5%
Q2 24
21.2%
23.5%
Capex Intensity
DXCM
DXCM
TER
TER
Q1 26
Q4 25
8.1%
5.8%
Q3 25
6.7%
6.1%
Q2 25
8.1%
7.7%
Q1 25
8.4%
9.3%
Q4 24
11.2%
7.6%
Q3 24
11.2%
7.0%
Q2 24
6.6%
6.1%
Cash Conversion
DXCM
DXCM
TER
TER
Q1 26
0.66×
Q4 25
1.10×
1.09×
Q3 25
2.33×
0.41×
Q2 25
1.69×
2.32×
Q1 25
1.74×
1.63×
Q4 24
1.99×
1.93×
Q3 24
1.48×
1.14×
Q2 24
1.95×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons